Avidian Wealth Enterprises’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $760K | Sell |
1,516
-525
| -26% | -$252K | 0.02% | 384 |
|
|
2026
Q1 | $1M | Buy |
2,041
+669
| +49% | +$363K | 0.03% | 287 |
|
|
2025
Q4 | $795K | Buy |
1,372
+131
| +11% | +$74.1K | 0.03% | 269 |
|
|
2025
Q3 | $602K | Buy |
1,241
+159
| +15% | +$74K | 0.02% | 332 |
|
|
2025
Q2 | $439K | Sell |
1,082
-239
| -18% | -$99.9K | 0.02% | 363 |
|
|
2025
Q1 | $657K | Buy |
1,321
+188
| +17% | +$102K | 0.03% | 258 |
|
|
2024
Q4 | $590K | Buy |
1,133
+6
| +0.5% | +$3.3K | 0.03% | 266 |
|
|
2024
Q3 | $697K | Sell |
1,127
-67
| -6% | -$39.7K | 0.03% | 241 |
|
|
2024
Q2 | $660K | Buy |
1,194
+71
| +6% | +$40.7K | 0.03% | 245 |
|
|
2024
Q1 | $652K | Buy |
1,123
+506
| +82% | +$284K | 0.03% | 225 |
|
|
2023
Q4 | $328K | Sell |
617
-312
| -34% | -$151K | 0.02% | 327 |
|
|
2023
Q3 | $470K | Sell |
929
-36
| -4% | -$19.2K | 0.03% | 268 |
|
|
2023
Q2 | $504K | Sell |
965
-2,420
| -71% | -$1.31M | 0.03% | 263 |
|
|
2023
Q1 | $1.95M | Sell |
3,385
-140
| -4% | -$78.9K | 0.11% | 140 |
|
|
2022
Q4 | $1.94M | Buy |
3,525
+941
| +36% | +$499K | 0.13% | 123 |
|
|
2022
Q3 | $1.31M | Buy |
2,584
+613
| +31% | +$343K | 0.09% | 129 |
|
|
2022
Q2 | $1.07M | Buy |
1,971
+109
| +6% | +$60K | 0.08% | 160 |
|
|
2022
Q1 | $1.1M | Sell |
1,862
-218
| -10% | -$125K | 0.07% | 181 |
|
|
2021
Q4 | $1.39M | Buy |
2,080
+420
| +25% | +$262K | 0.09% | 152 |
|
|
2021
Q3 | $948K | Sell |
1,660
-192
| -10% | -$105K | 0.07% | 136 |
|
|
2021
Q2 | $934K | Sell |
1,852
-39
| -2% | -$18.4K | 0.07% | 138 |
|
|
2021
Q1 | $863K | Buy |
1,891
+103
| +6% | +$49.2K | 0.07% | 138 |
|
|
2020
Q4 | $833K | Sell |
1,788
-204
| -10% | -$95.7K | 0.08% | 127 |
|
|
2020
Q3 | $880K | Sell |
1,992
-569
| -22% | -$235K | 0.1% | 107 |
|
|
2020
Q2 | $928K | Sell |
2,561
-810
| -24% | -$272K | 0.13% | 93 |
|
|
2020
Q1 | $956K | Buy |
3,371
+1,684
| +100% | +$531K | 0.15% | 74 |
|
|
2019
Q4 | $548K | Hold |
1,687
| – | – | 0.08% | 107 |
|
|
2019
Q3 | $491K | Sell |
1,687
-167
| -9% | -$47.8K | 0.08% | 102 |
|
|
2019
Q2 | $544K | Sell |
1,854
-4,414
| -70% | -$1.22M | 0.13% | 65 |
|
|
2019
Q1 | $1.72M | Buy |
6,268
+4,605
| +277% | +$1.15M | 0.38% | 29 |
|
|
2018
Q4 | $372K | Hold |
1,663
| – | – | 0.13% | 52 |
|
|
2018
Q3 | $406K | Buy |
1,663
+14
| +0.8% | +$3.22K | 0.13% | 67 |
|
|
2018
Q2 | $341K | Buy |
1,649
+31
| +2% | +$6.58K | 0.11% | 66 |
|
|
2018
Q1 | $334K | Buy |
1,618
+49
| +3% | +$10.3K | 0.11% | 67 |
|
|
2017
Q4 | $298 | Hold |
1,569
| – | – | 0.08% | 80 |
|
|
2017
Q3 | $297K | Hold |
1,569
| – | – | 0.11% | 63 |
|
|
2017
Q2 | $274K | Hold |
1,569
| – | – | 0.11% | 64 |
|
|
2017
Q1 | $241K | Hold |
1,569
| – | – | 0.09% | 72 |
|
|
2016
Q4 | $221K | Sell |
1,569
-389
| -20% | -$57.4K | 0.1% | 74 |
|
|
2016
Q3 | $311K | Buy |
+1,958
| New | +$302K | 0.13% | 54 |
|
Other funds holding TMO
Avidian Wealth Enterprises's TMO Position: Q2 2026 in Review
Avidian Wealth Enterprises reduced its Thermo Fisher Scientific (TMO) stake by 26% in Q2 2026, selling an estimated $252K and leaving 1,516 shares worth $760K. The position accounts for 0.02% of the portfolio, ranked #384.
Avidian Wealth Enterprises first reported a position in TMO in Q3 2016 and has held it in 40 quarters since. The position peaked at $1.95M in Q1 2023. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Avidian Wealth Enterprises held 1,516 shares of Thermo Fisher Scientific worth $760K as of Q2 2026.
- Avidian Wealth Enterprises sold 525 Thermo Fisher Scientific shares in Q2 2026, an estimated $252K.
- Thermo Fisher Scientific made up 0.02% of Avidian Wealth Enterprises's portfolio in Q2 2026, its #384 holding.
- Avidian Wealth Enterprises first reported a position in Thermo Fisher Scientific in Q3 2016 and has held it in 40 quarters since.
- Avidian Wealth Enterprises's Thermo Fisher Scientific position peaked at $1.95M in Q1 2023.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Avidian Wealth Enterprises's 13F filing for Q2 2026, filed 24 Jul 2026.